DOCSLIB.ORG

Development of a Low Cost Portable Fluorometry Technology and Quantification of Cannabinoids in Body Fluids

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Development of a Low Cost Portable Fluorometry Technology and Quantification of Cannabinoids in Body Fluids DOT HS 804 009 DEVELOPMENT OF A LOW COST PORTABLE FLUOROMETRY TECHNOLOGY AND QUANTIFICATION OF CANNABINOIDS IN BODY FLUIDS J. L. Valentine P. J. Bryant P.L. Gutshall 0. H. M. Gan B. H. C. Niu P. Psaltis University of Missouri-Kansas City 2411 Holmes Street Kansas City, Missouri 64108 Contract No. DOT HS-4-00968 Contract Amt. $69,651.00 ^^EaS OF TRANS^4 'z W 4rES OE 00' APRIL 1919 FINAL REPORT Document is available to the U.S. public through The National Technical Information Service, Springfield, Virginia 22161 Prepared For U.S. DEPARTMENT OF TRANSPORTATION National Highway Traffic Safety Administration Washington, D.C. 20590 This document is disseminated under the sponsorship of the Department of Transportation in the interest of information exchanca. The United States Govern­ ment assumes no liability for its contents or use thereof. Technical Report Documentation Page 1. Report No. 2. Gooernmeni Accession No. 3. Recipient's Catalog No. DOT HS-804 009 4. Title and Subtitle - S. Report Date Development of a Low Cost Portable Fluorometry Tech- May 4, 1977 nology and. Quantification of Cannabinoids in, Body 6. Performing Organization Code Fluids 8. Performing Organization Report No. 7. Author's) J.L. Valentine, P.J. Bryant, P.L. Gutshall, O.H.M. Gan, B.H.C. Niu, and P. Psaltis 9. Performing Organisation Nome and Address 10. Work Unit No. (TRAIS) University of Missouri-Kansas City 241.1 Holmes Street 11. Contract or G rant No. Kansas City, Missouri 64108 USDOT HS 4 00968 :13. Type of Report and Period Covered 12. Sponsoring. Agency Nome and Address Final Report June 28, 1975-June 28, 1976 14. Sponsoring Agency Code 13 Supplementary Notes 16 Abstroct Tec h no l ogy was d eveloped for determining o9 -tetrahydrocannabinol (I) and it ' s major metabolite.ll-nor-o9-tetr.ahydrocannabinol-9-carboxylic acid (II) in human blood plasma utilizing high pressure liquid chromatography (hplc)-ultraviolet (uv) detection. The methods were found to be capable of determining 10 ng of I or II in 1 ml of human plasma. A third type of assay method was developed for identifying in human saliva one of the major constituents of marijuana, cannabinol (III). Results indicated that III photolytically converted to a highly' fluorescent compound in the absence of air. Using this technique, a limited study of marijuana smoker's saliva and saliva from non-marijuana smokers to which I and III had been added was conducted. This study demonstrated that 1 ng/ml of III can be detected in saliva. 17. Key Words 18. Distribution Statement. Marijuana, hplc, fluorometry, blood, Document is available to the public saliva through the National Technical Information Service, Springfield, Va. 22161 19. Security Clossif. (of this report) 20. Security Clossif. (of this page) 21. No. of Pages 22. Price Unclassified Unclassified Form DOT F 1700.7 (8-72) Reproduction of form and completed page is authorized METRIC CONVERSION. FACTORS . -- _ .- ._ _ . e - - n .?: .- ?a Approximate Conversions lo Metric Measures .. --- -.. - -- .. Approximate Conversions from Metric Mea,surrs - .- - .- - ?4 . - .. Symbol . When Yon Know Mulriplv by Te ftnl Srmb~l - :7. Symbol When You Know Multiply by To Find Symbol .-.- - - N -.-. m -- - .. LENGTH -- .- F; LENGTH - . - m mtlfonplers 0.08 tnches n - E ~n, CP~I~VP(PI- 0.4 anches n -. mete,< 3.3 (QCI It n lncher '2.5 cent\rrators c W' - - f ,.. wtcrc fl feel 30 CPntlllYIIIlF ..,. 4 .-- - - 1.1 yard* ~d - ... i-. h~lnretprs, 0.6 miles mi . 0.9 m+.tt,rr - vd yards - - . m, mtl~s 1.6 ~J~~>PIPIF i -- -- - r- -- -. - .- --. - . - -..-- AREA AREA -- - -c -- . - P - - . .-. c".' quare centemete,s - - 0.16 square ~nches tn2 In2 square ~nches 6.5 SQ!$~CPrnnt~~r?!ers CT* - -. 5 n,. square wlers - :: 12 square vards rd 112 square feet 0.09 sqst~reret~rs m- -- square k~lareters ' - -- kd mq2 - - 0.4 squat* milts yd2 square vards 0.8 ~q,.dr*-l*rs 7- -- --- -f 11 ,1 [email protected] 2.5 . - --.- acres n.,> square rt~lrs 2.6 suu,>re k,im->eters kvL - - - . - ------ acres 0.4 h?rl.treq ha - .-- - - 0 -- ---- - - - -..- MASS (weight) -- ---:.___- MASS (weight) .- --- 9 -- -- - - - r( grams 0.035 wnce- 02 P* 01 ounces 28 grams 9 . - - - --- kr( kbloqrams 2.2 mds !b patnds 0.45 koloqrams hq - - . Ih - - - lwrnes ilOOO kg) , 1 .I sh& tons shwl tons 0.9 IO~IIPS I - -=-. I - - - .. - .. .. 12000 Ibl b -. -- --.-. 0 -- . C VOLUME -- - -*. VOL'JME - -..- . - - - --- 0, ' -- -. .- - - mt mill~ltters 0.03 flu~dumces 1. oi ISP teaspoons 5 mtll~llters T l - - ,- -- - - I Tbsp tablespoons 15 mlll,l,ters rn 1 --- -- OJ tilers 2.1 pjnts' c' 11 oz Iluld ounces 30 n~all~ltlers m 1 w -- >-.- I liters 1.06 quarts u: 9--- c CLIPS' 0.24 lrlers I -- -z- r- I l~fets 0.26 gallons -- - 7' PI pints 0.47 lst~rs I - -- v3 ctlhlc rnetcrs cnlhic lee! - - -- I 35 , - - .. ql qtmrts 0.95 l~l~ft I -- --.- . cuh8r wters 1.3 cuhlc yards ,t3 - --.- i~al gallons 3.8 I-t~rt I - -- - -- fti cub~~feet 0.03 ctch~c!I-#,I,,~S - .- ". -- ----- -. vd3 cubic yards 0.76 cuhlc nr'.tcrs v1 b. -- --- Lo -- -.- TEMPERATURE (exrct) - -.- - - . - --.. .- TEMPERATURE .(exact! -- 4 -I --- --- C Celsrus 9.5 llhen Fahrenhsct , - -- lamperat\tre temo~ralure . - - -..~ .-. .- add 321 . ' F Fahrenhett 5 9 latter Celsaus C - .--- - C -- --. temperat~~te s~htr~~cling twnpvratlore - -- --- or - .- - -_ . 321 -- .-= ____- F . 32 98-6 .RP .-- - c4 - --- -- -49 -0 4 0 8 0 120 I60 203 I --. --- : , : . , , , , , , \ , , , ,. , ! I ., I , L. .. ..ic ". ., .,,, . 4 , -- -= .-. t4; ./I ;'.' 411'11 '~'i'1' 'I' It2 4 . 0" , -? 2 - .... - - 60 -, ,.d" ,,?,,,Ib .,,. , ,,,.. , . ' : 3.8 ,.,,: .,,, i i . ii. I..,. - -... - .- - 60 -2t> V CV 1;; - . -- 37 C -- 5 OC SUMMARY Technology was developed for determining 09-tetrahydrocannabinol (A9-THC) and its major metabolite 11-nor-49-tetrahydrocannabinol-9-carboxylic acid (9­ C02H-69-THC) in human blood plasma utilizing high pressure liquid chromatography (hplc) and ultraviolet (uv) detection. The method developed for analysis of 69-THC was accomplished using an extraction of 1 ml of plasma with petroleum ether followed by normal phase hplc analysis. With the method, the lower prac­ tical limit of quantification was found to be 10 ng/ml, but a detection limit of S ng/ml was readily achieved. Thus the method would be useful for quantifying 69-THC in the one-hour period following marijuana smoking. The precision and accuracy of the method was comparable to the previously developed hplc-ms methodology. For. the analysis of 9-C02H-A9-THC, an hplc-uv method was developed utilizing a reverse phase column. Although the lower practical quantification limit was found to be 1.0 ng/ml of plasma, the plasma levels determined in.several marijuana smokers were found to give a response greater than that observed for a 100 ng/ml standard. Mass spectrometry was used to demonstrate that the quantified peak in the hplc analysis was consistant with the mass spectrum of 9-C'0.2H-a9-THC. The developed method was used to determine the plasma levels of 9-CO 2H-ATHC in both marijuana smokers and patients receiving G9-THC. Results indicated that 9-CO 2H-o9-THC does not give a smooth plasma decay curve as does 09-THC and that levels remain quite high for 24 hours following marijuana smoking. This assay method may be of practical value in identifying a marijuana user. A third type of assay method was also developed during the study for one of the major constituents of marijuana, viz. cannabinol (CBN). Spectral studies with the various cannabinoids indicated that CBN could be photolytically converted to CBN I if air was excluded and to CBN II and CBN III in the presence of air. Of these photolytic compounds, CBN I proved to be highly fluorescent. An assay iii Summary .Page 2 was developed for saliva which allowed CBN present from marijuana smoking to be detected. A limited study was conducted using saliva from both marijuana smokers and nonsmokers as well as the saliva from nonsmokers to which 1 ng/ml of CBN was added. The results indicate that a marijuana smoker can be.identified if at least 1 ng/ml of. CBN is present in the saliva. All three of the methods developed during the study represent an advance in reducing the complexity, time and expense in assaying for marijuana use. In the case of a9-THC and 9-CO2H-A9-THC, the developed method is somewhat more involved since quantification is the major objective. With the CBN assay, the procedure is not lengthy but gives only qualitative information as to marijuana use. All three analysis utilize comparatively simple techniques. Although not all clinical laboratories. are equipped with hplc instruments to perform the A9-,THC and/or 9-CO7H-d9-THC assays, there. would be the. universal ability to perforn the CBN assay since a readily available fluorometer is used. iv The authors are F ateful to the National Institute on Drug Abuse for additional financial support of this work. v Table of Contents (Text) Introduction 1 Experimental A.­ Ultraviolet Studies of the Cannabinoids . ... 1 B.­ Fluorescence Studies of the Cannabinoids . 2 C.­ Design and Construction of a Fluormetric Flow Cell . 5 D.­ Analysis of A -THC in Human Plasma Using Sephadex-LH-20 and Hplc . 5 E.­ Analysis of 0 9 -THC in Human Plasma Using HPLC-UV . ... 7 9 F. Analysis of 9-CO 2H-p -THC in Human Plasma Using HPLC-UV . 7 Results and Discussion A. Hplc-Fluorescence Studies . .­ . 8 B.­ Hplc-Ultraviolet Studies for p9-Tetrahydrocannabinol . 10 9 C.­ Hplc-Ultraviolet Studies on 11-nor-p -tetrahydrocannabinol-9­ carboxylic Acid .
Load more

Recommended publications
  • Cannabinoids in the Pathophysiology of Skin Inflammation
    molecules Review Cannabinoids in the Pathophysiology of Skin Inflammation Cristian Scheau 1 , Ioana Anca Badarau 1, Livia-Gratiela Mihai 1, Andreea-Elena Scheau 2, Daniel Octavian Costache 3, Carolina Constantin 4,5, Daniela Calina 6 , Constantin Caruntu 1,7,*, Raluca Simona Costache 8,* and Ana Caruntu 9,10 1 Department of Physiology, “Carol Davila” University of Medicine and Pharmacy, 050474 Bucharest, Romania; [email protected] (C.S.); [email protected] (I.A.B.); [email protected] (L.-G.M.) 2 Department of Radiology and Medical Imaging, Fundeni Clinical Institute, 022328 Bucharest, Romania; [email protected] 3 Department of Dermatology, “Carol Davila” Central Military Emergency Hospital, 010825 Bucharest, Romania; [email protected] 4 Immunology Department, ”Victor Babes” National Institute of Pathology, 050096 Bucharest, Romania; [email protected] 5 Department of Pathology, Colentina University Hospital, 020125 Bucharest, Romania 6 Department of Clinical Pharmacy, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania; [email protected] 7 Department of Dermatology, “Prof. N. Paulescu” National Institute of Diabetes, Nutrition and Metabolic Diseases, 011233 Bucharest, Romania 8 Gastroenterology and Internal Medicine Clinic, Carol Davila University Central Emergency Military Hospital, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania 9 Department of Oral and Maxillofacial Surgery, “Carol Davila” Central Military Emergency Hospital, 010825 Bucharest, Romania; [email protected] 10 Faculty of Medicine, “Titu Maiorescu” University, 031593 Bucharest, Romania * Correspondence: [email protected] (C.C.); [email protected] (R.S.C.); Tel.: +40-745-086-978 (C.C.) Academic Editor: Eric J. Downer Received: 30 December 2019; Accepted: 2 February 2020; Published: 4 February 2020 Abstract: Cannabinoids are increasingly-used substances in the treatment of chronic pain, some neuropsychiatric disorders and more recently, skin disorders with an inflammatory component.
    [Show full text]
  • Marinol Cannabidiol C21H30O2 Trade Name
    Cannabinoids are a group of terpenophenolic compounds secreted by Cannabis flowers that provide relief from a wide array of symptoms including, pain, nausea, and inflammation. They operate by imitating the body’s natural endocannabinoids, which activate to maintain internal stability and overall health. When consumed, cannabinoids bind to receptor sites throughout the brain (CB1 receptors) and body (CB2 receptors). Different cannabinoids have different effects based on their binding affinity for each receptor. By targeting specific cannabinoids at these receptors, different types of relief can be achieved. Presently, there are at least 113 different cannabinoids isolated from Cannabis—each exhibiting varied effects. THC Tetrahydrocannabinol C21H30O2 Trade name: Marinol Legal Status: US – Schedule I, Schedule II (as Cesamet), Schedule III (as Marinol) OH CA – Schedule II UK – Class B AU – S8 (controlled) H Psychoactive Tetrahydrocannabinol (THC) is typically the most abundant cannabinoid present in cannabis products on the market today. THC has very high psychoactive characteristics and is associated with the ‘high’ and euphoria experienced when using cannabis products. When smoked or ingested, THC binds to cannabinoid receptors throughout the body and affects memory, O coordination, concentration, pleasure, and time perception. H Medicinal Benefits Analgesic • Anti-nauseant • Appetite Stimulant Reduces Glaucoma Symptoms Sleep Aid • Reduces Anxiety and PTSD Symptoms CBD Cannabidiol C21H30O2 Trade name: Epidiolex OH Legal Status: US – Schedule I CA – Schedule II UK – POM (Perscription only) H AU – S4 (Perscription only) non-psychoactive Cannabidiol (CBD) is a major phytocannabinoid and accounts for up to 40% of the plant’s extract. Due to its lack of psychoactivity and HO non-interference with motor and psychological functions, it is a leading candidate for a wide variety of medical applications.
    [Show full text]
  • Recent Developments in Cannabis Chemistry
    Recent Developments in Cannabis Chemistry BY ALEXANDER T. SHULGIN, Ph.D. The marijuana plant Cannabis sativa contains a bewildering Introduction array of organic chemicals. As is true with other botanic species, there are representatives of almost all chemical classes present, including mono- and sesquiterpenes, carbohy- drates, aromatics, and a variety of nitrogenous compounds. Interest in the study of this plant has centered primarily on the resinous fraction, as it is this material that is invested with the pharmacological activity that is peculiar to the plant. This resin is secreted by the female plant as a protective agent during seed ripening, although it can be found as a microscopic exudate through the aerial portions of plants of either sex. The pure resin, hashish or charas, is the most potent fraction of the plant, and has served as the source material for most of the chemical studies. The family of chemicals that has been isolated from this source has been referred to as the cannabinoid group. It is unique amongst psychotropic materials from plants in that there are no alkaloids present. The fraction is totally nitro- gen-free. Rather, the set of compounds can be considered as analogs of the parent compound cannabinol (I), a fusion product of terpene and a substituted resorcinol. Beyond the scope of this present review are such questions as the distribution of these compounds within the plant, the bo- tanic variability resulting from geographic distribution, the diversity of pharmacological action assignable to the several Reprinted from Journal of Psychedelic Drugs, vol. II, no. 1, 197 1. 397 398 Marijuana: Medical Papers distinct compounds present, and the various preparations and customs of administration.
    [Show full text]
  • 2 Spice English Presentation
    Spice Spice contains no compensatory substances Специи не содержит компенсационные вещества Spice is a mix of herbs (shredded plant material) and manmade chemicals with mind-altering effects. It is often called “synthetic marijuana” because some of the chemicals in it are similar to ones in marijuana; but its effects are sometimes very different from marijuana, and frequently much stronger. It is most often labeled “Not for Human Consumption” and disguised as incense. Eliminationprocess • The synthetic agonists such as THC is fat soluble. • Probably, they are stored as THC in cell membranes. • Some of the chemicals in Spice, however, attach to those receptors more strongly than THC, which could lead to a much stronger and more unpredictable effect. • Additionally, there are many chemicals that remain unidentified in products sold as Spice and it is therefore not clear how they may affect the user. • Moreover, these chemicals are often being changed as the makers of Spice alter them to avoid the products being illegal. • To dissolve the Spice crystals Acetone is used endocannabinoids synhtetic THC cannabinoids CB1 and CB2 agonister Binds to cannabinoidreceptor CB1 CB2 - In the brain -in the immune system Decreased avtivity in the cell ____________________ Maria Ellgren Since some of the compounds have a longer toxic effects compared to naturally THC, as reported: • negative effects that often occur the day after consumption, as a general hangover , but without nausea, mentally slow, confused, distracted, impairment of long and short term memory • Other reports mention the qualitative impairment of cognitive processes and emotional functioning, like all the oxygen leaves the brain.
    [Show full text]
  • INTRODUCTION One of the Tasks of a Pharmacologist Is the Classification of Drugs
    NEUROPSYCHOPHARMACOLOGIC STUDIES OF MARIJUANA: SOME SYNTHETIC AND NATURAL THC DERIVATIVES IN ANIMALS AND MAN* Edward F. Domino Department of Pharmacology, University of Michigan, Ann Arbor 48104 and Lafayette Clinic, Detroit, Mich. 48207 INTRODUCTION One of the tasks of a pharmacologist is the classification of drugs. Marijuana and its derivatives pose some problems. Legally marijuana has been classified as a narcotic, yet pharmacologically it is quite different. Mankind has known about the Cannabis plant from which marijuana and other products are obtained for more than 4,708 years. A considerable body of data is available to describe its gross effects. Over the centuries it has been called a depressant, euphoriant, ine- briant, intoxicant, hallucinogen, psychotomimetic, sedative-hypnotic-anesthetic, and stimulant. Perhaps more than any other drug it is a social irritant that elicits rather remarkable behavior reactions in both users and nonusers. Moreau’ in 1845, employed it to produce a model psychosis, thus initiating the fashion to study hallucinogens as a means of gaining insights into mental illness. Lewin2 classified Cannabis as one of the “phantastica: hallucinating substances.” One text on hallucinogens3 does not even refer to Cannabis, but another does? There are some aspects of the subjective effects of both LSD-25 and Cannabis that are similar, yet the latter produces sedative effects, no significant sympatho- mimetic actions, and no cross-tolerance to LSD-25. Hollister5 reviewed the re- cent findings on the effects in man of marijuana and its putative active ingredient Ag-THC, stressing that current investigators have, for the most part, confirmed the Cannabis-induced clinical syndromes long known to occur.
    [Show full text]
  • Application of High Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances Joshua Zolton Seither [email protected]
    Florida International University FIU Digital Commons FIU Electronic Theses and Dissertations University Graduate School 4-25-2018 Application of High Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances Joshua Zolton Seither [email protected] DOI: 10.25148/etd.FIDC006565 Follow this and additional works at: https://digitalcommons.fiu.edu/etd Part of the Chemistry Commons Recommended Citation Seither, Joshua Zolton, "Application of High Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances" (2018). FIU Electronic Theses and Dissertations. 3823. https://digitalcommons.fiu.edu/etd/3823 This work is brought to you for free and open access by the University Graduate School at FIU Digital Commons. It has been accepted for inclusion in FIU Electronic Theses and Dissertations by an authorized administrator of FIU Digital Commons. For more information, please contact [email protected]. FLORIDA INTERNATIONAL UNIVERSITY Miami, Florida APPLICATION OF HIGH RESOLUTION MASS SPECTROMETRY FOR THE SCREENING AND CONFIRMATION OF NOVEL PSYCHOACTIVE SUBSTANCES A dissertation submitted in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY in CHEMISTRY by Joshua Zolton Seither 2018 To: Dean Michael R. Heithaus College of Arts, Sciences and Education This dissertation, written by Joshua Zolton Seither, and entitled Application of High- Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances, having been approved in respect to style and intellectual content, is referred to you for judgment. We have read this dissertation and recommend that it be approved. _______________________________________ Piero Gardinali _______________________________________ Bruce McCord _______________________________________ DeEtta Mills _______________________________________ Stanislaw Wnuk _______________________________________ Anthony DeCaprio, Major Professor Date of Defense: April 25, 2018 The dissertation of Joshua Zolton Seither is approved.
    [Show full text]
  • Model Scheduling New/Novel Psychoactive Substances Act (Third Edition)
    Model Scheduling New/Novel Psychoactive Substances Act (Third Edition) July 1, 2019. This project was supported by Grant No. G1799ONDCP03A, awarded by the Office of National Drug Control Policy. Points of view or opinions in this document are those of the author and do not necessarily represent the official position or policies of the Office of National Drug Control Policy or the United States Government. © 2019 NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. This document may be reproduced for non-commercial purposes with full attribution to the National Alliance for Model State Drug Laws. Please contact NAMSDL at [email protected] or (703) 229-4954 with any questions about the Model Language. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: NATIONAL ALLIANCE FOR MODEL STATE DRUG 1 LAWS, 1335 North Front Street, First Floor, Harrisburg, PA, 17102-2629. Model Scheduling New/Novel Psychoactive Substances Act (Third Edition)1 Table of Contents 3 Policy Statement and Background 5 Highlights 6 Section I – Short Title 6 Section II – Purpose 6 Section III – Synthetic Cannabinoids 13 Section IV – Substituted Cathinones 19 Section V – Substituted Phenethylamines 23 Section VI – N-benzyl Phenethylamine Compounds 25 Section VII – Substituted Tryptamines 28 Section VIII – Substituted Phenylcyclohexylamines 30 Section IX – Fentanyl Derivatives 39 Section X – Unclassified NPS 43 Appendix 1 Second edition published in September 2018; first edition published in 2014. Content in red bold first added in third edition. © 2019 NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. This document may be reproduced for non-commercial purposes with full attribution to the National Alliance for Model State Drug Laws.
    [Show full text]
  • The Use of Cannabinoids in Animals and Therapeutic Implications for Veterinary Medicine: a Review
    Veterinarni Medicina, 61, 2016 (3): 111–122 Review Article doi: 10.17221/8762-VETMED The use of cannabinoids in animals and therapeutic implications for veterinary medicine: a review L. Landa1, A. Sulcova2, P. Gbelec3 1Faculty of Medicine, Masaryk University, Brno, Czech Republic 2Central European Institute of Technology, Masaryk University, Brno, Czech Republic 3Veterinary Hospital and Ambulance AA Vet, Prague, Czech Republic ABSTRACT: Cannabinoids/medical marijuana and their possible therapeutic use have received increased atten- tion in human medicine during the last years. This increased attention is also an issue for veterinarians because particularly companion animal owners now show an increased interest in the use of these compounds in veteri- nary medicine. This review sets out to comprehensively summarise well known facts concerning properties of cannabinoids, their mechanisms of action, role of cannabinoid receptors and their classification. It outlines the main pharmacological effects of cannabinoids in laboratory rodents and it also discusses examples of possible beneficial use in other animal species (ferrets, cats, dogs, monkeys) that have been reported in the scientific lit- erature. Finally, the article deals with the prospective use of cannabinoids in veterinary medicine. We have not intended to review the topic of cannabinoids in an exhaustive manner; rather, our aim was to provide both the scientific community and clinical veterinarians with a brief, concise and understandable overview of the use of cannabinoids in veterinary
    [Show full text]
  • WO 2018/018152 Al 01 February 2018 (01.02.2018) W !P O IPCT
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2018/018152 Al 01 February 2018 (01.02.2018) W !P O IPCT (51) International Patent Classification: A61K 9/68 (2006 .0 1) A61P 25/04 (2006 .0 1) A61K 31/05 (2006.01) C07C 39/23 (2006.01) A61K 31/352 (2006.01) C07D 311/80 (2006.01) (21) International Application Number: PCT/CA20 17/050904 (22) International Filing Date: 28 July 2017 (28.07.2017) (25) Filing Language: English (26) Publication Langi English (30) Priority Data: 15/222,019 28 July 2016 (28.07.2016) US (72) Inventor; and (71) Applicant: GREENSPOON, Allen [CA/CA]; Ml-414 Victoria Avenue South, Hamilton, Ontario L8L 5G8 (CA). (74) Agent: TANDAN, Susan; Gowling WLG (Canada) LLP, One Main Street West, Hamilton, Ontario L8P 4Z5 (CA). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
    [Show full text]
  • The Effects of Cannabinoids on Stress-Coping
    Utah State University DigitalCommons@USU All Graduate Theses and Dissertations Graduate Studies 5-2021 The Effects of Cannabinoids on Stress-Coping Behaviors and Neuroendocrinological Measures in Chronic Unpredtictable Stress: A Preclinical Systematic Review and Meta-Analysis Noa Reuveni Utah State University Follow this and additional works at: https://digitalcommons.usu.edu/etd Part of the Psychology Commons Recommended Citation Reuveni, Noa, "The Effects of Cannabinoids on Stress-Coping Behaviors and Neuroendocrinological Measures in Chronic Unpredtictable Stress: A Preclinical Systematic Review and Meta-Analysis" (2021). All Graduate Theses and Dissertations. 8098. https://digitalcommons.usu.edu/etd/8098 This Thesis is brought to you for free and open access by the Graduate Studies at DigitalCommons@USU. It has been accepted for inclusion in All Graduate Theses and Dissertations by an authorized administrator of DigitalCommons@USU. For more information, please contact [email protected]. THE EFFECTS OF CANNABINOIDS ON STRESS-COPING BEHAVIORS AND NEUROENDOCRINOLOGICAL MEASURES IN CHRONIC UNPREDTICTABLE STRESS: A PRECLINICAL SYSTEMATIC REVIEW AND META-ANALYSIS by Noa Reuveni A thesis submitted in partial fulfillment of the requirements for the degree of MASTER OF SCIENCE in Psychology Approved: __________________ __________________ Sara Freeman, Ph.D. Scott Bates, Ph.D. Co-Major Professor Co-Major Professor __________________ __________________ Diana Meter, Ph.D. Sarah Schwartz, Ph.D. Committee Member Committee Member __________________ __________________ Tyler Renshaw, Ph.D. D. Richard Cutler, Ph.D. Committee Member Interim Vice Provost for Graduate Studies UTAH STATE UNIVERSITY Logan, Utah 2021 ii Copyright © Noa Reuveni 2021 All Rights Reserved iii ABSTRACT The Effects of Cannabinoids on Stress-Coping Behaviors and Neuroendocrinological Measures in Chronic Unpredictable Stress: A Preclinical Systematic Review and Meta-Analysis by Noa Reuveni, Master of Science Utah State University, 2021 Major Professors: Dr.
    [Show full text]
  • Table of Natural Cannabinoids
    Table of Natural Cannabinoids Scientific research continues to develop and further identify individual cannabinoids in cannabis strains and how they affect symptoms of illnesses suffered by patients. The table below identifies the chemical properties of the natural cannabinoids found in the average strains of cannabis. Levels of each of these chemicals will vary with varietal strain, growing method, and plant age. Individual cannabinoids can be enhanced or eliminated depending on need. Cannabigerol- type (CBG) Cannabigerol Cannabigerol Cannabigerovarin (E)-CBG-C monomethyl (E)-CBGV-C 5 Cannabinerolic 3 ether acid A (E)-CBGM-C 5 (Z)-CBGA-C A A 5 Cannabigerolic Cannabigerolic Cannabigerovarinic acid acid A acid A A (E)-CBGA-C5 A monomethyl (E)-CBGVA-C3 A ether (E)-CBGAM- C5 A Cannabichrom ene-type (CBC) (±)- (±)- Cannabichromen (±)- Cannabivarichromene, (±)- e Cannabichrome (±)- Cannabichrome CBC-C5 nic acid A Cannabichromevarin varinic CBCA-C5 A CBCV-C3 acid A CBCVA-C3 A Cannabidiol- type (CBD) 1 | Page (−)-Cannabidiol Cannabidiol Cannabidiol-C4 (−)- Cannabidiorc CBD-C5 momomethyl CBD-C4 Cannabidivarin ol ether CBDV-C3 CBD-C1 CBDM-C5 Cannabidiolic Cannabidivarini acid c acid CBDA-C5 CBDVA-C3 Cannabinodiol- type (CBND) Cannabinodiol Cannabinodivar CBND-C5 in CBND-C3 Tetrahydrocan nabinol-type (THC) 9 9 9 Δ - Δ - Δ - Δ9- Tetrahydrocanna Tetrahydrocan Tetrahydrocannabivarin 9 Tetrahydrocan binol nabinol-C4 Δ -THCV-C3 9 9 nabiorcol Δ -THC-C5 Δ -THC-C4 9 Δ -THCO-C1 9 9 Δ -Tetrahydro- Δ9-Tetrahydro- Δ -Tetrahydro- Δ9-Tetrahydro- cannabinolic
    [Show full text]
  • Cannabinoid Receptor Antagonists Counteract Sensorimotor Gating Deficits in the Phencyclidine Model of Psychosis
    Neuropsychopharmacology (2007) 32, 2098–2107 & 2007 Nature Publishing Group All rights reserved 0893-133X/07 $30.00 www.neuropsychopharmacology.org Cannabinoid Receptor Antagonists Counteract Sensorimotor Gating Deficits in the Phencyclidine Model of Psychosis ,1 2,3 4 5 3,6 Martina Ballmaier* , Marco Bortolato , Cristina Rizzetti , Michele Zoli , GianLuigi Gessa , 1,6 4,6 Andreas Heinz and PierFranco Spano 1Department of Psychiatry and Psychotherapy, Charite´ University Medicine, Campus Mitte, Berlin, Germany; 2Department of Pharmacology, 3 4 University of California, Irvine, USA; Department of Neuroscience, Bernard B Brodie, University of Cagliari, Cagliari, Italy; Department of 5 Biomedical Sciences and Biotechnologies, Brescia University Medical School, Brescia, Italy; Department of Biomedical Sciences, University of Modena and Reggio Emilia, Modena, Italy Clinical and laboratory findings suggest that cannabinoids and their receptors are implicated in schizophrenia. The role of cannabinoids in schizophrenia remains however poorly understood, as data are often contradictory. The primary aim of this study was to investigate whether the cannabinoid CB1 receptor antagonists rimonabant and AM251 are able to reverse deficits of sensorimotor gating induced by phencyclidine and to mimic the ‘atypical’ antipsychotic profile of clozapine. The prepulse inhibition (PPI) of the startle reflex was used to measure deficits of sensorimotor gating. PPI-disruptive effects of phencyclidine and their antagonism by rimonabant, AM251, and clozapine were studied in rats. The effects of rimonabant were carefully examined taking into account dose ranges, vehicle, and route of administration. We also examined the ability of rimonabant to reduce the PPI-disruptive effects of dizocilpine and apomorphine. Rimonabant as well as AM251 significantly counteracted the phencyclidine-disruptive model of PPI, comparable to the restoring effect of clozapine; no augmentation effect was observed with rimonabant and clozapine as cotreatment.
    [Show full text]